A Phase 3 Open-Label Clinical Study to Evaluate the Safety and Tolerability of Rebiotix RBX2660 (microbiota suspension) in Subjects with Recurrent Clostridium difficile Infection Save

Date Added
September 10th, 2019
PRO Number
Pro00089814
Researcher
Scott Curry

List of Studies

Silhouette
Keywords
Digestive System, Infectious Diseases
Summary

An open-label clinical study in which all subjects will receive the same investigational drug, for people with recurrent Clostridium difficile infection (CDI), which is an infection in the intestines. This infection causes severe diarrhea. Recurrent Clostridium difficile (C. diff) infection is being studied as part of a medical research study for an investigational new drug called RBX2660, an enema made of a solution of stool (poop or feces).

Institution
MUSC
Recruitment Contact
Scott Curry
843-876-8646
currysr@musc.edu

Change_preferences

-- OR --

Create_login